These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 30194449)
1. Arginine refolds, stabilizes, and restores function of mutant pVHL proteins in animal model of the VHL cancer syndrome. Shmueli MD; Levy-Kanfo L; Haj E; Schoenfeld AR; Gazit E; Segal D Oncogene; 2019 Feb; 38(7):1038-1049. PubMed ID: 30194449 [TBL] [Abstract][Full Text] [Related]
2. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293 [TBL] [Abstract][Full Text] [Related]
3. Hypoxia and cell cycle regulation of the von Hippel-Lindau tumor suppressor. Liu W; Xin H; Eckert DT; Brown JA; Gnarra JR Oncogene; 2011 Jan; 30(1):21-31. PubMed ID: 20802534 [TBL] [Abstract][Full Text] [Related]
4. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Kaelin WG Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019 [TBL] [Abstract][Full Text] [Related]
5. [Von-Hippel-Lindau (VHL) protein function by initiation and progression of renal cancer]. Moch H Pathologe; 2008 Nov; 29 Suppl 2():149-52. PubMed ID: 18751708 [TBL] [Abstract][Full Text] [Related]
6. Clinical and functional properties of novel VHL mutation (X214L) consistent with Type 2A phenotype and low risk of renal cell carcinoma. Sorrell AD; Lee S; Stolle C; Ellenhorn J; Grix A; Kaelin WG; Weitzel JN Clin Genet; 2011 Jun; 79(6):539-45. PubMed ID: 20560986 [TBL] [Abstract][Full Text] [Related]
7. Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1alpha interactions. Knauth K; Bex C; Jemth P; Buchberger A Oncogene; 2006 Jan; 25(3):370-7. PubMed ID: 16261165 [TBL] [Abstract][Full Text] [Related]
8. Coalescing lessons from oxygen sensing, tumor metabolism, and epigenetics to target VHL loss in kidney cancer. Chakraborty AA Semin Cancer Biol; 2020 Dec; 67(Pt 2):34-42. PubMed ID: 32209418 [TBL] [Abstract][Full Text] [Related]
9. Identification of novel VHL target genes and relationship to hypoxic response pathways. Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735 [TBL] [Abstract][Full Text] [Related]
10. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones. Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918 [TBL] [Abstract][Full Text] [Related]
12. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hoffman MA; Ohh M; Yang H; Klco JM; Ivan M; Kaelin WG Hum Mol Genet; 2001 May; 10(10):1019-27. PubMed ID: 11331612 [TBL] [Abstract][Full Text] [Related]
13. The von Hippel-Lindau tumor suppressor protein promotes c-Cbl-independent poly-ubiquitylation and degradation of the activated EGFR. Zhou L; Yang H PLoS One; 2011; 6(9):e23936. PubMed ID: 21949687 [TBL] [Abstract][Full Text] [Related]
14. The VHL tumor suppressor and HIF: insights from genetic studies in mice. Kapitsinou PP; Haase VH Cell Death Differ; 2008 Apr; 15(4):650-9. PubMed ID: 18219317 [TBL] [Abstract][Full Text] [Related]
15. VHL mutations linked to type 2C von Hippel-Lindau disease cause extensive structural perturbations in pVHL. Knauth K; Cartwright E; Freund S; Bycroft M; Buchberger A J Biol Chem; 2009 Apr; 284(16):10514-22. PubMed ID: 19228690 [TBL] [Abstract][Full Text] [Related]
16. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720 [TBL] [Abstract][Full Text] [Related]
18. The von Hippel-Lindau protein forms fibrillar amyloid assemblies that are mitigated by the anti-amyloid molecule Purpurin. Kumar V; Kaushik V; Kumar S; Levkovich SA; Gupta P; Laor Bar-Yosef D; Gazit E; Segal D Biochem Biophys Res Commun; 2024 Jan; 690():149250. PubMed ID: 38039781 [TBL] [Abstract][Full Text] [Related]
19. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma. Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414 [TBL] [Abstract][Full Text] [Related]
20. Computational and experimental characterization of dVHL establish a Drosophila model of VHL syndrome. Shmueli MD; Schnaider L; Herzog G; Gazit E; Segal D PLoS One; 2014; 9(10):e109864. PubMed ID: 25310726 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]